The study was carried out to explore previous clinical findings with cabozantinib in castration-resistant prostate cancer patients with bone metastases showing a 67 percent rate of bone scan response and other clinical signs of effect...MEI Pharma Inc., of San Diego, presented data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a preclinical in vivo model of recurrent epithelial ovarian cancer

Array BioPharma Inc., of Boulder, Colo., reported clinical data at the International Myeloma Workshop in Kyoto, Japan, showing that ARRY-520, a selective KSP inhibitor, demonstrated single-agent activity in heavily pretreated patients with relapsed or refractory multiple myeloma, with 19 months median overall survival and a 16 percent overall response rate...Cerulean Pharma Inc., of Cambridge, Mass., will present Phase II data for investigational nanopharmaceutical product CRLX101 at the American

Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, acts potently against breast cancer cell lines that lack expression of the estrogen and progesterone receptors, while also lacking HER2 amplification, i.e., TNBC

Cerulean Pharma Inc., of Cambridge, Mass., said CRLX101 achieved the predefined gating criterion for advancement into the second stage of a Phase II trial in advanced ovarian cancer...EntreMed Inc., of Rockville, Md., said it submitted a clinical trial application in China to conduct global trials of ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor, in triple-negative breast cancer patients

Acura intends to complete clinical testing for a new drug submission via the 505(b)(2) pathway in the first half of 2014...BioAlliance Pharma SA, of Paris, said the European Independent Board of Experts held its first meeting on the ReLive Phase III trial evaluating the efficacy of Livatag (doxorubicin Transdrug) in primary liver cancer and recommended continuing the global, multicenter, randomized study without modification. (See BioWorld International, June 29, 2011...About 79.6 achieved clinical

Dompe Group, of Milan, Italy, said it presented the status of a clinical trial to evaluate the safety and pharmacokinetic profile of Reparixin, administered orally in combination with paclitaxel in women with metastatic breast cancer at the San Antonio Breast Cancer Symposium

The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase improves kidney function and reduces the need for dialysis...Certainly, the pharma industry is very aware of what we're doing and interested in it," Andrews said...Puma is working on neratinib, an

The paper cites data from an open-label, Phase II trial of single-agent neratinib in advanced HER2-positive breast cancer, which enrolled both trastuzumab-refractory (n=66) and trastuzumab-naive (n=70) patients, and demonstrated modest clinical activity in both cohorts...The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene

The study is designed to assess the clinical impact of the absorption profile of BIOD-123 relative to currently marketed mealtime insulin analogues...Glenmark's partner, Paris-based Sanofi SA, has licensed all rights to the drug and is carrying out clinical development...Zealand Pharma A/S, of Copenhagen, Denmark, said it dosed the first patient in a Phase I study of ZP2929, a dual-acting glucagon/GLP-1 peptide agonist, in development for treating patients with Type II diabetes and/or patients with

BHR Pharma LLC, of Phoenix, said it reached its SyNAPSe clinical trial enrollment midpoint of 590 patients...ICT-121 is the second dendritic-cell-based vaccine to enter clinical trials

Cerulean Pharma Inc., of Cambridge, Mass., completed enrollment in a Phase II trial of CRLX101, in non-small-cell lung cancer (NSCLC) and dosed its first patient in a Phase Ib/IIa trial of the same product in combination with Avastin (bevacizumab, Roche AG) in metastatic renal cell carcinoma (mRCC...Protalix BioTherapeutics Inc., of Carmiel, Israel, reported clinical data for taliglucerase alfa showing that at 36 months, patients with Gaucher disease had significant improvement in bone marrow fat

Antisense Pharma GmbH, of Regensburg, Germany presented complete data from its Phase I/II study of trabedersen, an antisense compound that specifically inhibits expression of transforming growth factor beta 2 (TGF-β2) – a protein which is overexpressed in advanced tumors – in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer...CytRx Corp., of Los Angeles, reported Phase Ib/II data showing that tumor-targeting doxorubicin conjugate INNO-206 produced a clinical benefit

Genta Inc., of Berkeley Heights, N.J., said it has accrued its first patient in a trial of tesetaxel as initial chemotherapy for advanced or recurrent breast cancer...ImmunoCellular Therapeutics Ltd., of Woodland Hills, Calif., will present new data from its previously completed Phase I trial of ICT-107 in glioblastomoa multiforme at the American Society of Clinical Oncology meeting in Chicago

Assuming the final clinical study report supports the preliminary findings, RedHill said it will consider filing for U.S...RedHill licensed rights to the extended-release version of the anti-emetic drug, dubbed RHB-102, from Scolr Pharma Inc., of Bothell, Wash...Syndax Pharmaceuticals Inc., of Waltham, Mass., said investigators in the department of breast medical oncology at The University of Texas MD Anderson Cancer Center initiated a Phase I/II study combining lead product entinostat with lapatinib

Serendipitously, independent clinical studies of the antecedent biomarkers of AD seem to have corroborated Satori's approach, he added...Despite the huge number of failures, small and large pharma companies have been pouring billions of dollars into the development of molecules that leave a lot to be desired...The company also has an exclusive distribution agreement with Uman Pharma Inc., of Quebec, to commercialize gemcitabine in the U.S. The compound went off patent last year in the U.S

In mouse breast cancer models, VS-507 decreased CSC biomarkers...Proceeds will support clinical trials of Androxal and Proellex

EyeGate Pharma Inc., of Waltham, Mass., enrolled the first patient in a Phase III pivotal study of its lead product, EGP-437, for the treatment of anterior uveitis...The double-blind, placebo-controlled, randomized clinical trial in 40 patients who had received at least one anti-TNF treatment was designed to establish the best dose and administration schedule, based on immune response to the Kinoid...multicenter, 70-patient Phase II clinical trial with Fibrocaps – a dry powder topical tissue sealant

The randomized, controlled trial enrolled heavily pre-treated breast cancer patients unlikely to benefit from any approved therapies and whose tumors express GPNMB...UCB Pharma SA, of Brussels, Belgium, began a trial (EXXELERATE) of Cimzia (certolizumab pegol) plus methotrexate compared with Humira (adalimumab) plus methotrexate for rheumatoid arthritis

The compound demonstrated preliminary but encouraging single-agent clinical activity in both indications...Niiki Pharma Inc., of Hoboken, N.J., reported preclinical combination studies showing that its lead product, NKP-1339, demonstrated synergistic activity in both in vitro and in vivo models when given with a broad range of antitumor agents...In vitro studies tested the drug in combination with cisplatin, oxaliplatin, 5-FU, docetaxel, doxorubicin, gemcitabine, Tarceva (erlotinib, Astellas Pharma